Non-small cell lung cancer

Common Name(s)

Non-small cell lung cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Non-small cell lung cancer" for support, advocacy or research.

Free to Breathe

Free to Breathe is a partnership of lung cancer survivors, advocates, researchers, healthcare professionals and industry leaders united in the belief that every person with lung cancer deserves a cure. Free to Breathe is dedicated to doubling lung cancer survival by 2022.

Last Updated: 16 Oct 2014

View Details
Logo
Lung Cancer Foundation of America

LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

Last Updated: 28 Aug 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Non-small cell lung cancer" for support, advocacy or research.

Free to Breathe

Free to Breathe is a partnership of lung cancer survivors, advocates, researchers, healthcare professionals and industry leaders united in the belief that every person with lung cancer deserves a cure. Free to Breathe is dedicated to doubling lung cancer survival by 2022.

http://www.freetobreathe.org

Last Updated: 16 Oct 2014

View Details
Logo
Lung Cancer Foundation of America

LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

http://www.LCFAmerica.org

Last Updated: 28 Aug 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Non-small cell lung cancer" returned 3961 free, full-text research articles on human participants. First 3 results:

Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer.
 

Author(s): Ashish Saxena, Misako Nagasaka, Zujun Li, Daniel J Becker, Benjamin P Levy

Journal: Oncology (Williston Park, N.Y.). 2014 Jun;28(6):526, 528, 530, 534.

 

Last Updated: 19 Aug 2014

Go To URL
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
 

Author(s): Solange Peters, Stefan Zimmermann, Alex A Adjei

Journal: Cancer Treat. Rev.. 2014 Sep;40(8):917-26.

 

The development of orally active small molecule inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC). Patients with activating mutations of the EGFR gene show sensitivity to, and clinical benefit from, treatment ...

Last Updated: 28 Jul 2014

Go To URL
Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
 

Author(s): Y Hu, M-m Hu, G-L Shi, Y Han, B-L Li

Journal: Eur J Surg Oncol. 2014 Sep;40(9):1136-42.

 

Angiogenesis is regulated by a balance of pro-angiogenic and anti-angiogenic factors. Vascular endothelial growth factor (VEGF) and endostatin respectively represents a frequent component of inducers and inhibitors in the process of angiogenesis. The ratio of VEGF/endostatin may reflect ...

Last Updated: 11 Aug 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Non-small cell lung cancer" returned 502 free, full-text review articles on human participants. First 3 results:

ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent.
 

Author(s): Joe Yujiao Chang, Larry L Kestin, R Bryan Barriger, Indrin J Chetty, Mark E Ginsburg, Sanath Kumar, Billy W Loo, Benjamin Movsas, Andreas Rimner, Kenneth E Rosenzweig, Thomas E Stinchcombe, Gregory M M Videtic, Henning Willers

Journal:

 

Concurrent chemotherapy/radiotherapy has been considered the standard treatment for patients with a good performance status and inoperable stage III non-small-cell lung cancer (NSCLC). Three-dimensional chemoradiation therapy and intensity-modulated radiation therapy have been reported ...

Last Updated: 21 Aug 2014

Go To URL
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
 

Author(s):

Journal: Lancet. 2014 May;383(9928):1561-71.

 

Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to establish the effect of preoperative chemotherapy ...

Last Updated: 5 May 2014

Go To URL
First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
 

Author(s): Neha Gupta, Hassan Hatoum, Grace K Dy

Journal: Int J Nanomedicine. 2014 ;9():209-21.

 

Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of cases. Paclitaxel has a broad spectrum of activity against various malignancies, including ...

Last Updated: 8 Jan 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
 

Status: Recruiting

Condition Summary: Non-small Cell Lung Cancer; Advanced Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer

 

Last Updated: 15 May 2014

Go to URL
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
 

Status: Recruiting

Condition Summary: Cachexia; Fatigue; Pulmonary Complications; Radiation Toxicity; Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer

 

Last Updated: 28 Mar 2014

Go to URL
Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies
 

Status: Recruiting

Condition Summary: Non-Small Cell Lung Cancer, Small Cell Lung Cancer; Platinum Responsive Malignancies

 

Last Updated: 1 Oct 2012

Go to URL